RU2016151235A - Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус - Google Patents

Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус Download PDF

Info

Publication number
RU2016151235A
RU2016151235A RU2016151235A RU2016151235A RU2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A
Authority
RU
Russia
Prior art keywords
human
antibody
specifically binds
cynomolgus monkey
cells
Prior art date
Application number
RU2016151235A
Other languages
English (en)
Russian (ru)
Other versions
RU2016151235A3 (cg-RX-API-DMAC10.html
Inventor
Георг ТИФЕНТАЛЕР
Эккехард Мёсснер
Валерия ЛИФКЕ
Йозеф Платцер
Соня ОФФНЕР
Кристиане Йегер
Мирко РИТТЕР
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2016151235A publication Critical patent/RU2016151235A/ru
Publication of RU2016151235A3 publication Critical patent/RU2016151235A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2016151235A 2014-05-28 2015-05-22 Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус RU2016151235A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14170140.9 2014-05-28
EP14170140 2014-05-28
EP14180572.1 2014-08-11
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (2)

Publication Number Publication Date
RU2016151235A true RU2016151235A (ru) 2018-06-28
RU2016151235A3 RU2016151235A3 (cg-RX-API-DMAC10.html) 2019-01-18

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016151235A RU2016151235A (ru) 2014-05-28 2015-05-22 Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус

Country Status (13)

Country Link
US (3) US20170233475A1 (cg-RX-API-DMAC10.html)
EP (2) EP3763739A1 (cg-RX-API-DMAC10.html)
JP (1) JP6738285B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170003591A (cg-RX-API-DMAC10.html)
CN (1) CN106459201A (cg-RX-API-DMAC10.html)
AU (1) AU2015266077A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016022819A2 (cg-RX-API-DMAC10.html)
CA (1) CA2942453A1 (cg-RX-API-DMAC10.html)
IL (1) IL247740A0 (cg-RX-API-DMAC10.html)
MX (1) MX2016015389A (cg-RX-API-DMAC10.html)
RU (1) RU2016151235A (cg-RX-API-DMAC10.html)
SG (1) SG11201609950YA (cg-RX-API-DMAC10.html)
WO (1) WO2015181098A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN118126180A (zh) * 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
JP2020521791A (ja) 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US11319371B2 (en) 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
CN111108119B (zh) * 2017-09-21 2022-11-15 上海药明生物技术有限公司 新型抗CD3ε抗体
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
PE20230389A1 (es) * 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
JP7851303B2 (ja) * 2020-09-24 2026-04-24 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒトｃｄ３イプシロンに結合する新規なヒト抗体
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
WO2023183766A1 (en) * 2022-03-20 2023-09-28 Abcellera Biologics Inc. Anti-cd3 antibodies and t-cell engagers and methods of use
JP2025513714A (ja) * 2022-03-22 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃｄ３に特異的な脱免疫抗体
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
SI2155788T1 (sl) * 2007-04-03 2012-11-30 Amgen Res Munich Gmbh Bispecifični vezavni element specifičen za križane vrste
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Also Published As

Publication number Publication date
US20200325224A1 (en) 2020-10-15
BR112016022819A2 (pt) 2018-01-16
MX2016015389A (es) 2017-04-13
US20200299385A1 (en) 2020-09-24
EP3149041A1 (en) 2017-04-05
SG11201609950YA (en) 2016-12-29
AU2015266077A1 (en) 2016-09-29
CN106459201A (zh) 2017-02-22
JP2017516786A (ja) 2017-06-22
CA2942453A1 (en) 2015-12-03
IL247740A0 (en) 2016-11-30
KR20170003591A (ko) 2017-01-09
RU2016151235A3 (cg-RX-API-DMAC10.html) 2019-01-18
WO2015181098A1 (en) 2015-12-03
JP6738285B2 (ja) 2020-08-12
US20170233475A1 (en) 2017-08-17
EP3763739A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP2017516786A5 (cg-RX-API-DMAC10.html)
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
JP2013538057A5 (cg-RX-API-DMAC10.html)
JP2022523442A5 (cg-RX-API-DMAC10.html)
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
RU2016100892A (ru) Антитела против tweakr и их применение
PE20230408A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
RU2017104642A (ru) Новое антитело против tie-2 человека
JP2016512034A5 (cg-RX-API-DMAC10.html)
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
JP2021500916A5 (cg-RX-API-DMAC10.html)
AR103713A1 (es) Anticuerpos contra tau y sus usos
PE20071055A1 (es) Anticuerpos anti mn
JP2017508475A5 (cg-RX-API-DMAC10.html)
MX342782B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
JP2014526898A5 (cg-RX-API-DMAC10.html)
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
WO2013064700A3 (en) Chimeric human-camel antigens and their use
RU2017105596A (ru) Антитела к церамиду

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200806